Diabetes
Page 1 • 3 itemsUnlock global diabetes market insights. Get critical pharma intelligence on R&D, regulatory approvals, and investment opportunities for diabetes treatments.
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval
FDA approves LANGLARA (insulin glargine-aldy) as interchangeable biosimilar to Lantus for diabetes treatment in adults and pediatric patients.
GoodRx Offers Ozempic Pill Access for Type 2 Diabetes Patients at $149 Monthly
GoodRx now provides self-pay access to Novo Nordisk's oral Ozempic for type 2 diabetes patients starting at $149/month nationwide.
SAB Biotherapeutics SAB-142 Shows C-Peptide Preservation in Type 1 Diabetes Phase 1 Trial
SAB-142 preserved C-peptide in all 4 Type 1 diabetes patients, with 3 showing super responder profiles and improved glycemic control in Phase 1 trial.